Cytokinetics analyst coverage

WebApr 11, 2024 · What analysts cover Cytokinetics? Cytokinetics has been rated by Bank of America, Cantor Fitzgerald, HC Wainwright, JMP Securities, Mizuho, Needham & Company LLC, Oppenheimer, The Goldman Sachs Group, and UBS Group in the past 90 days. Stock Ratings Reports and Tools Top-Rated Brokerages Stock Ratings Screener Free Ratings … WebApr 10, 2024 · Trevor Immelman faced the tall task of being named CBS Sports’ lead golf analyst in January, replacing Nick Faldo in the 18th tower, but he soared into this weekend’s coverage of the Masters.

Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Acquired by …

WebApr 2, 2024 · Financials. In 2024, Cytokinetics reported revenues of $2.0 million for Q4 and $94.6 million for the full year, compared to $55.6 million and $70.4 million in the same periods of 2024. This ... WebApr 12, 2024 · Wall Street Analyst Weigh In. Several brokerages recently weighed in on CYTK. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Cytokinetics in a ... on this day september 21 https://tipografiaeconomica.net

Cytokinetics Reports Third Quarter 2024 Financial Results

WebSep 28, 2024 · Cytokinetics Incorporated CYTK Competitors News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders Cytokinetics Incorporated News... Web17 rows · Mar 27, 2024 · PRESS RELEASES Cytokinetics, Inc. INVESTORS & MEDIA 2024 Press Releases Webcast 22nd Annual Needham Virtual Healthcare Conference … WebMar 7, 2024 · Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Mizuho Posted by Defense World Staff on Mar 7th, 2024 Mizuho assumed coverage on shares of Cytokinetics ( NASDAQ:CYTK – Get... on this day smithsonian

Cytokinetics Outlines Go-To-Market Strategy for Omecamtiv

Category:Cytokinetics Muscle Biology Therapies Home

Tags:Cytokinetics analyst coverage

Cytokinetics analyst coverage

2024 – Summer Analyst Internship – Financial Institutions Coverage …

WebSep 28, 2024 · News Profile Analyst Coverage 5 Yr. Financials Dividends Adv. Charts Earnings Options Price History Events Insiders WebAnalyst Coverage; Investor FAQ; IR/Media Contacts; Corporate Governance; Information Request; Email Alerts

Cytokinetics analyst coverage

Did you know?

WebApr 6, 2024 · Analyst Price Forecast Suggests 12.99% Upside As of April 6, 2024, the average one-year price target for Broadcom is $696.81. The forecasts range from a low of $589.84 to a high of $787.50. WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class …

WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media. ... Analyst Coverage. Investor FAQ. IR/Media Contacts. Corporate Governance. Information Request . Email Alerts . WebMar 31, 2024 · March 31, 2024 Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis. March 27, 2024 Cytokinetics Releases Inaugural Corporate Responsibility Report. March …

WebAnalyst Estimates Options Snapshot Stock Price Targets Yearly Numbers Estimates CYTK will report 2024 earnings on 02/23/2024 EPS Estimate 2024 2024 2024 2024 -10 -5 0 … WebMar 3, 2024 · Following the latest upgrade, the current consensus, from the 13 analysts covering Cytokinetics, is for revenues of US$54m in 2024, which would reflect a stressful 43% reduction in...

WebJan 7, 2024 · Royalty Pharma Extends Capital to Cytokinetics to Support the Commercial Launch of Omecamtiv Mecarbil and the Further Development of Aficamten; Royalty Pharma Purchases Royalties on Future Sales of Aficamten; Cytokinetics to Host Conference Call and Webcast Today at 8:30 a.m. ET; NEW YORK, NY and SOUTH SAN FRANCISCO, …

WebNov 3, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. on this day templateWebMay 24, 2024 · Below is a summary of how these 4 analysts rated Cytokinetics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … ios image recovery routerWeb1 day ago · Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd … on this day september 19thWebOur Corporate Responsibility Framework. Keep Patients at the Center of our Work. Continue to embed patient centricity across all stages of our business. Maintain strong … on this day trivia questions and answersWebApr 5, 2024 · According to analysts' consensus price target of $56.21, Cytokinetics has a forecasted upside of 60.7% from its current price of $34.99. Amount of Analyst … ios image view not showing on launchscreenWebCytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Stock Information Press Releases on this day twitterWebMar 1, 2024 · SOUTH SAN FRANCISCO, Calif., March 01, 2024(GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) reported financial results for the fourth … on this day september 30